4.4 Article

Monoclonal antibodies in multiple myeloma

期刊

PANMINERVA MEDICA
卷 63, 期 1, 页码 21-27

出版社

EDIZIONI MINERVA MEDICA
DOI: 10.23736/S0031-0808.20.04149-X

关键词

Multiple myeloma; Immunotherapy; Antibodies; monoclonal

向作者/读者索取更多资源

In recent years, the treatment landscape for multiple myeloma patients has seen significant advancements with the introduction of next-generation proteasome inhibitors, immunomodulatory derivatives, and monoclonal antibodies. Monoclonal antibodies offer a promising new approach with immune-based mechanisms that induce durable responses and have shown effectiveness in heavily pretreated or double refractory patients. These antibodies work through various pathways, including ADCC, ADCP, CDC, and the induction of signals on cell effectors, targeting key molecular pathways involved in the survival of malignant plasma cells.
Treatment of multiple myeloma (MM) patients has radically changed over the last years following the introduction of next generation proteasome inhibitors (PI) and immunomodulatory derivative (IMiDs). In the last years, one further therapeutic option for MM patients is represented by monoclonal antibodies (MoAbs), that seem to change the paradigm of MM treatment, particularly for heavily pretreated or double refractory to a PI and IMiDs patients. Antibodies have an immune-based mechanism, induce durable responses with limited toxicity and combine well with existing therapies. The therapeutic effects are prevalently obtained by means of antibody-dependent cellular cytotoxicity (ADCC), antibodydependent cell-mediated phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and concurrently by the induction of signals on cell effectors. Immunotherapeutic strategies offer a new and exciting approach to target key molecular pathways that continue to be implicated in the survival of malignant plasma cells. These targets include cell surface proteins (CD38, CD138 [SDC1], B cell maturation antigen [BCMA, TNFRSF17]), cytokines that play a role in plasma cell survival and proliferation (interleukin 6 [IL6] and B cell activating factor), signal regulators of bone metabolism (RANKL [TNFSF11], DKK1) and regulators of the immune system (PD-1[PDCD1], PD-L1[CD274]). This article focuses on new MoAbs and related innovative immunotherapeutic modalities currently under investigation in the treatment landscape of MM.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据